Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise independent medical judgment, consider individual patient circumstances, and consult the most current clinical guidelines and expert opinions when making diagnostic and treatment decisions. This reference does not replace the need for direct patient evaluation and consultation with specialists.

Kawasaki Disease

Overview

• Definition: Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute, self-limited vasculitis of unknown etiology that primarily affects medium-sized arteries, especially the coronary arteries. It is characterized by persistent fever and a constellation of mucocutaneous and nodal manifestations, with coronary artery aneurysms (CAAs) being the most serious complication.
• Epidemiology:
  • Incidence: It is the most common cause of acquired heart disease in children in developed countries. Incidence varies globally, with the highest rates in Japan (estimated 265 per 100,000 children <5 years) and other Asian countries. In the United States, incidence is approximately 19-25 per 100,000 children <5 years.
  • Age: Predominantly affects children aged 6 months to 5 years, with a peak incidence around 1-2 years. It is rare in infants younger than 3 months and children older than 8 years, though these age groups are at higher risk for incomplete presentation and severe complications.
  • Sex: Slightly more common in males (male-to-female ratio of approximately 1.5:1).
  • Ethnicity: Higher incidence in children of East Asian descent (Japanese, Korean, Chinese) compared to Caucasian children.
  • Seasonality: Tends to occur more frequently in winter and spring months, suggesting a possible infectious trigger.
• Classification:
  • Complete (Classic) Kawasaki Disease: Diagnosed when a child presents with fever for at least 5 days and at least 4 of the 5 principal clinical criteria (see "Signs and Symptoms" below).
  • Incomplete (Atypical) Kawasaki Disease: Diagnosed when a child presents with prolonged unexplained fever (≥5 days) and fewer than 4 of the principal criteria, but has laboratory evidence of inflammation and/or echocardiographic findings suggestive of KD. This form is more common in infants and older children and carries a higher risk of delayed diagnosis and coronary artery complications.

Pathophysiology

• Mechanism: KD is believed to be an acute, systemic vasculitis mediated by an aberrant immune response to an infectious trigger in genetically susceptible individuals.
  • Immune Activation: An initial trigger (likely viral or bacterial antigen) leads to widespread activation of the innate and adaptive immune systems.
  • Cytokine Storm: High levels of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6, IL-8, IFN-γ) are released, leading to systemic inflammation.
  • Endothelial Damage: These cytokines cause endothelial cell activation and injury in blood vessels, particularly medium-sized muscular arteries.
  • Infiltration: Inflammatory cells (T cells, macrophages, neutrophils) infiltrate the vessel walls, leading to destruction of the media and elastic lamina, proliferation of the intima, and perivascular cuffing.
  • Aneurysm Formation: The destruction of arterial wall integrity, especially in the coronary arteries, predisposes to dilation and aneurysm formation. Thrombosis can occur within aneurysms.
  • Genetic Predisposition: Polymorphisms in genes involved in immune regulation (e.g., ITPKC, ORAI1, CASP3, FCGR2A) are associated with increased susceptibility and/or disease severity.
• Risk Factors:
  • Age: Infants <6 months and children >8 years are at higher risk for incomplete KD and increased risk of coronary artery complications.
  • Ethnicity: East Asian descent (e.g., Japanese, Korean) due to genetic predispositions.
  • Sex: Male sex is a minor risk factor.
  • Genetics: Familial clustering (though rare) and specific genetic polymorphisms.
  • Environmental/Infectious Triggers: Undefined, but seasonality and clustering suggest an environmental trigger. No specific pathogen has been definitively identified.
• Protective Factors: None definitively identified. Early diagnosis and timely, appropriate treatment (IVIG) are critical in preventing complications rather than preventing the disease itself.

Clinical Presentation

Signs and Symptoms

The diagnosis of complete KD requires fever for at least 5 days AND at least 4 of the 5 principal clinical criteria. - Cardinal Features (The "5 Principal Criteria" + Fever): 1. Fever: Persistent, high-spiking fever, typically ≥39°C (102.2°F), unresponsive to antibiotics, lasting at least 5 days (the diagnostic criterion). May last 1-2 weeks if untreated. 2. Bilateral Non-Exudative Conjunctival Injection: Redness of the whites of the eyes without pus or discharge. Usually resolves within 1-2 weeks. 3. Oral Mucosal Changes: * Erythema and cracking of the lips. * "Strawberry tongue" (red, enlarged papillae). * Diffuse redness of the oral and pharyngeal mucosa. 4. Peripheral Extremity Changes: * Acute Phase: Erythema and edema of the hands and feet (palms and soles are often bright red and swollen). * Subacute Phase (1-3 weeks after fever onset): Periungual desquamation (peeling of skin on fingertips and toes), typically starting around nails and extending to palms/soles. 5. Polymorphous Rash: Non-vesicular, non-bullous rash. Highly variable in appearance (macular, papular, erythematous, urticarial, scarlatiniform). Often appears on the trunk and extremities, can be generalized. 6. Cervical Lymphadenopathy: Acute non-suppurative cervical lymphadenopathy, usually unilateral, firm, non-tender, at least 1.5 cm in diameter. Present in about 50-75% of cases and is often the least consistently present criterion.

• Early Signs:

  • Irritability is common.
  • Anorexia, abdominal pain, diarrhea, vomiting (non-specific gastrointestinal symptoms).
  • Arthralgia or arthritis, often affecting large joints.
  • Bacillus Calmette-Guérin (BCG) inoculation site erythema and induration (in regions where BCG vaccine is common).

• Advanced Signs:

  • Cardiac Involvement (most serious):
    • Myocarditis: Tachycardia, gallop rhythm, decreased cardiac output.
    • Pericarditis: Pericardial rub, effusion.
    • Valvulitis: Mitral or aortic regurgitation.
    • Coronary Artery Aneurysms (CAAs): Often asymptomatic but can lead to ischemia or infarction.
  • Desquamation: Peeling of skin, especially around the fingertips and toes, typically begins 1-3 weeks after fever onset, as acute symptoms resolve.

• Atypical Presentations (Incomplete KD):

  • Infants (<6 months): Often present with prolonged fever and only 1-3 principal criteria, or with irritability, extreme lethargy, or only cardiac involvement. Higher risk of delayed diagnosis and CAAs.
  • Older Children (>8 years): May present with fever and arthralgia/arthritis, sometimes mistaken for rheumatic fever.
  • Fever of Unknown Origin (FUO): Children with KD may present as FUO if classical criteria are not yet present or are subtle. High index of suspicion needed in prolonged fever unresponsive to antibiotics with systemic inflammation.

Physical Examination

Systematic examination is crucial to identify the principal criteria and signs of complications. - Inspection: - General Appearance: Irritability, lethargy. - Skin: Erythema and edema of hands/feet, polymorphous rash (trunk, extremities, perineum), desquamation (later phase). - Eyes: Bilateral conjunctival injection (limbal sparing is common). - Oral Cavity: Erythematous, cracked lips; strawberry tongue; diffuse pharyngeal injection. - Neck: Unilateral cervical lymphadenopathy. - Palpation: - Extremities: Tenderness or swelling of joints. - Neck: Palpation of lymph nodes for size (>1.5 cm) and consistency. - Abdomen: May reveal hepatomegaly or gallbladder hydrops (non-specific findings). - Pulse: Tachycardia, bounding pulses; assess for peripheral pulse discrepancies (rare, but suggest large vessel involvement). - Auscultation: - Cardiac: Tachycardia, gallop rhythm, muffled heart sounds (pericardial effusion), murmurs (mitral regurgitation, aortic regurgitation). - Lungs: Clear (pneumonitis is rare). - Special Tests: None specific for KD on physical exam alone. Focus on comprehensive assessment for the diagnostic criteria and signs of complications.

Diagnostic Approach

History Taking

• Key Questions:
  • Fever characteristics: Onset, duration, maximum temperature, response to antipyretics, persistence despite antibiotics.
  • Associated symptoms: Rash (description, timing), eye redness (exudate?), lip/oral changes (eating/drinking difficulties), hand/foot swelling (pain, redness), neck swelling (unilateral/bilateral, painful?).
  • Other systemic symptoms: Irritability, joint pain/swelling, abdominal pain, vomiting, diarrhea, cough, runny nose.
  • Exposures: Sick contacts, recent travel, pet exposure, insect bites, medication history (rule out drug reactions).
  • Past medical history: Any prior episodes of similar illness? Underlying conditions?
  • Immunization status: Especially BCG, as a reaction at the site can be a clue.
• Red Flags:
  • Fever >5 days with incomplete criteria: Especially in infants <6 months, or if highly irritable or showing signs of cardiac involvement.
  • Signs of cardiac dysfunction: Tachycardia out of proportion to fever, gallop rhythm, muffled heart sounds, poor perfusion.
  • Significant lethargy or altered mental status: May suggest CNS involvement.
  • Persistent fever despite IVIG treatment: Suggests refractory disease.

Laboratory Tests

No single diagnostic lab test for KD; diagnosis is clinical, supported by inflammatory markers. - First-Line: Used to support diagnosis and assess inflammation: - Complete Blood Count (CBC) with Differential: * Leukocytosis with neutrophilia (WBC count often >15,000/mm³ in acute phase). * Anemia (normochromic, normocytic) common during acute phase. * Thrombocytosis (platelet count >450,000/mm³) usually develops in the second or third week of illness and can persist for weeks. (Elevated ESR, CRP, and low albumin typically precede thrombocytosis). - Erythrocyte Sedimentation Rate (ESR): Markedly elevated (>40 mm/hr, often >100 mm/hr) in acute phase. - C-Reactive Protein (CRP): Markedly elevated (>3 mg/dL, often >10 mg/dL) in acute phase. Normalization indicates resolution of acute inflammation. - Serum Albumin: Often low (<3.5 g/dL) due to capillary leak syndrome. - Alanine Aminotransferase (ALT) / Aspartate Aminotransferase (AST): Mildly elevated in ~10% of cases. - Urinalysis: Sterile pyuria (presence of white blood cells in urine without bacterial infection) is common. - Confirmatory: No specific confirmatory lab test. Diagnosis remains clinical. - In cases of incomplete KD, additional lab criteria for systemic inflammation (in addition to ESR/CRP elevation) can support diagnosis: * Albumin ≤3.0 g/dL * Anemia for age * Elevated ALT * Platelets ≥450,000/mm³ (after 7 days of fever) * WBC ≥15,000/mm³ * Sterile pyuria (>10 WBC/HPF) - Monitoring: - Acute Phase: Repeat CRP and ESR daily or every other day to assess response to IVIG. - Subacute/Convalescent Phase: CBC (to monitor platelets), CRP, ESR weekly or bi-weekly until normalized to monitor for persistent inflammation or the characteristic thrombocytosis.

Imaging

• Recommended:
  • Echocardiography (ECHO):
    • Initial: Performed at diagnosis or suspicion of KD (ideally within the first 7-10 days of illness). Evaluates for coronary artery dilation or aneurysms, myocarditis, pericardial effusion, valvular regurgitation, and global cardiac function.
    • Follow-up: Recommended at approximately 1-2 weeks and 4-6 weeks after disease onset (or after IVIG treatment) to monitor for the development or progression of coronary artery lesions, as CAAs can develop later.
    • Measurements: Z-scores (standardized scores based on body surface area) are used to define coronary artery abnormalities.
      • Coronary Artery Dilation: Z-score ≥2.0 and <2.5
      • Small Aneurysm: Z-score ≥2.5 and <5.0
      • Medium Aneurysm: Z-score ≥5.0 and <10.0
      • Large or Giant Aneurysm: Z-score ≥10.0 (absolute dimension >8 mm).
• Advanced:
  • Cardiac MRI (CMRI): May be used for detailed evaluation of coronary arteries and myocardial scarring/fibrosis, especially in cases with persistent or complex CAAs, or when echo views are suboptimal.
  • Coronary CT Angiography (CCTA): Can provide excellent anatomical detail of coronary arteries but involves radiation exposure, so generally reserved for specific indications (e.g., pre-surgical planning, or when CMRI is contraindicated).
  • Cardiac Catheterization with Angiography: Reserved for therapeutic interventions (e.g., percutaneous coronary intervention) or in cases where non-invasive imaging is insufficient to guide management of complex CAAs.

Management

Acute Management

The primary goal of acute management is to reduce inflammation, prevent coronary artery abnormalities, and treat complications. - Immediate: - Hospitalization: All patients with suspected or confirmed KD should be admitted to the hospital for observation, IVIG administration, and monitoring for potential complications. - Fluid Management: Maintain hydration. - Stabilization: - Intravenous Immunoglobulin (IVIG): * Dosage: Single dose of 2 g/kg infused over 10-12 hours. * Timing: Ideally administered within 7-10 days of fever onset to maximize effectiveness in preventing CAAs. Can still be beneficial after 10 days if there is ongoing inflammation (elevated CRP/ESR) or evidence of CAAs. * Mechanism: Modulates the immune response, reduces systemic inflammation, and prevents coronary artery damage. - Aspirin: * High-Dose Aspirin (Anti-inflammatory): * Dosage: 30-50 mg/kg/day (or 80-100 mg/kg/day in some older guidelines) divided into 4 doses (every 6 hours). * Duration: Continued until the patient is afebrile for 48-72 hours. * Low-Dose Aspirin (Antiplatelet): * Dosage: 3-5 mg/kg/day as a single daily dose. * Duration: Initiated after the high-dose regimen is completed. Continued until platelet count normalizes and follow-up echocardiogram shows no coronary artery abnormalities (typically 6-8 weeks). If CAAs are present, low-dose aspirin is continued indefinitely or until the aneurysm resolves. * Rationale: Prevents thrombus formation in inflamed or damaged coronary arteries. - Emergency: - Cardiovascular Compromise: In cases of severe myocarditis, pericardial effusion with tamponade, or severe valvular regurgitation, supportive care may include inotropes, diuretics, or pericardiocentesis. - Refractory Fever: If fever persists beyond 36 hours after IVIG completion, consider a second dose of IVIG or alternative therapies.

Chronic Management

Focused on long-term surveillance for coronary artery disease and management of established CAAs. - Pharmacological: - Low-Dose Aspirin: As described above, continued long-term if CAAs persist. - Anticoagulation: For patients with moderate-to-large CAAs (Z-score ≥5 or >6 mm absolute diameter) or giant CAAs (Z-score ≥10 or >8 mm absolute diameter), or those with multiple aneurysms, the risk of thrombosis is high. * Agents: Warfarin (target INR 2.0-2.5) or direct oral anticoagulants (DOACs) are often added to low-dose aspirin, or aspirin is replaced by anticoagulation depending on guidelines and clinical scenario. - Statins: For patients with persistent CAAs who develop dyslipidemia, statins may be considered to reduce the risk of accelerated atherosclerosis. - Non-pharmacological: - Activity Restriction: Children with current CAAs or a history of significant CAAs may require activity restrictions, particularly from competitive sports, until cleared by a cardiologist. - Healthy Lifestyle: Promote healthy diet and exercise to minimize cardiovascular risk factors in patients with a history of KD. - Vaccinations: Annual influenza vaccination is recommended for children on chronic aspirin therapy (to prevent Reye syndrome if infected with influenza or varicella). Varicella vaccine is also recommended. - Monitoring: - Echocardiography: Regular follow-up echoes based on the severity and persistence of CAAs. * No CAAs: Follow-up echo at 1-2 weeks and 4-6 weeks post-onset, then usually yearly for children <10 years post-KD. * Persistent CAAs: Follow-up intervals depend on aneurysm size and morphology (e.g., every 6-12 months for small/medium, more frequently for giant aneurysms). - Clinical Follow-up: Regular cardiology follow-up for assessment of cardiac status, medication management, and screening for cardiovascular risk factors. - Stress Testing: May be considered in adolescents or young adults with significant CAAs to assess for myocardial ischemia.

Treatment Algorithms

• First-Line:
  1. Diagnosis: Clinical diagnosis based on fever ≥5 days and ≥4 principal criteria (or incomplete KD criteria).
  2. Initial Treatment:
     • IVIG: Single dose 2 g/kg over 10-12 hours.
     • Aspirin: High-dose (30-50 mg/kg/day or 80-100 mg/kg/day) until afebrile for 48-72 hours, then transition to low-dose (3-5 mg/kg/day).
  3. Monitor Response: Assess for defervescence within 36 hours of IVIG completion. Monitor CRP/ESR.
• Second-Line (for IVIG-refractory KD):
  • Persistent fever or recurrence of fever >36 hours after IVIG:
    • Second dose of IVIG: Consider a second 2 g/kg dose of IVIG.
    • Corticosteroids:
      • Methylprednisolone pulse therapy: 30 mg/kg IV once daily for 1-3 days, then oral prednisone taper. Often used in conjunction with a second dose of IVIG.
      • Prednisolone/Prednisone: Oral daily dosage (e.g., 2 mg/kg/day initially, tapered over weeks).
    • Infliximab: A TNF-α inhibitor, single dose 5 mg/kg IV. Used in select cases of refractory KD, particularly if high risk for CAA.
• Refractory Cases (beyond second-line):
  • Additional Immunomodulators:
    • Cyclosporine: Calcineurin inhibitor.
    • Cyclophosphamide: Alkylating agent, for severe, life-threatening vasculitis.
    • Tocilizumab: An IL-6 receptor antagonist, emerging evidence for use in refractory cases.
    • Plasmapheresis: Rare, for severe, life-threatening refractory cases.
  • Consultation with experts in pediatric rheumatology or infectious disease is highly recommended for refractory cases.

Complications

• Common:
  • Thrombocytosis: Occurs in the subacute phase, typically resolves over weeks.
  • Gallbladder hydrops: Transient, generally benign.
  • Arthralgia/Arthritis: Common during the acute phase.
  • Gastrointestinal symptoms: Abdominal pain, diarrhea, vomiting.
• Serious:
  • Coronary Artery Aneurysms (CAAs): The most serious and specific complication. Occurs in 15-25% of untreated patients and 2-5% of IVIG-treated patients. Can lead to:
    • Thrombosis: Formation of clots within aneurysms, leading to acute coronary occlusion.
    • Myocardial Ischemia/Infarction: Due to thrombosis, stenosis, or occlusion of coronary arteries.
    • Rupture: Rare, but catastrophic complication of giant aneurysms.
    • Stenosis: Progressive narrowing of coronary arteries over time.
  • Myocarditis: Inflammation of the heart muscle, leading to decreased contractility, arrhythmias.
  • Pericarditis/Pericardial Effusion: Inflammation of the pericardium, potentially leading to tamponade.
  • Valvulitis: Most commonly mitral regurgitation.
  • Aneurysms of other arteries: Less common, but can affect peripheral, renal, mesenteric, or cerebral arteries.
  • Central Nervous System (CNS) involvement: Irritability, aseptic meningitis, facial nerve palsy, rarely stroke.
• Long-term:
  • Coronary Artery Disease (CAD): Patients with a history of CAAs are at increased risk for premature atherosclerosis and cardiovascular events later in life, even if aneurysms regress.
  • Recurrence: Rare (1-3% of cases), but possible.
  • Psychological impact: Chronic illness and frequent medical follow-ups can affect quality of life.

Prognosis

• Factors:
  • Presence and size of CAAs: The most significant prognostic factor. Patients with giant CAAs (Z-score ≥10 or >8 mm) have the highest risk of adverse long-term outcomes (stenosis, thrombosis, myocardial infarction).
  • Timeliness of IVIG treatment: Treatment within 10 days of fever onset significantly reduces the risk of CAAs.
  • Response to IVIG: IVIG-refractory disease is associated with a higher risk of CAA.
  • Age: Infants (<6 months) and older children (>8 years) are at higher risk for incomplete disease and subsequent CAAs.
• Survival: Mortality is low (<0.1%) in treated patients. Most deaths are due to myocardial infarction resulting from coronary artery thrombosis or rupture.
• Quality of Life: Most children with KD recover completely without long-term sequelae. However, those who develop significant CAAs require lifelong cardiologic follow-up and may have activity restrictions, long-term medication, and a potentially reduced quality of life due to the risk of cardiovascular events.

Prevention

• Primary: Currently, there are no known primary preventive measures for KD, as its exact etiology remains unknown. Research is ongoing to identify potential triggers and genetic predispositions.
• Secondary: Focuses on early diagnosis and prompt treatment to prevent complications.
  • Increased Awareness: Educating healthcare providers about KD, especially its atypical forms, to reduce diagnostic delays.
  • High Index of Suspicion: Clinicians should consider KD in any child with prolonged unexplained fever, particularly if accompanied by other suggestive symptoms or laboratory evidence of systemic inflammation.
  • Early IVIG Administration: Timely administration of IVIG (within 7-10 days of fever onset) is the most effective secondary prevention strategy against CAA formation.
• Tertiary: Aims to prevent long-term sequelae and manage established complications.
  • Lifelong Cardiac Surveillance: Regular echocardiograms and clinical follow-up for patients with a history of CAAs.
  • Antiplatelet/Anticoagulant Therapy: Appropriate pharmacotherapy to prevent thrombosis in CAAs.
  • Risk Factor Modification: Management of traditional cardiovascular risk factors (e.g., dyslipidemia, hypertension, obesity) in patients with a history of KD, especially those with persistent CAAs, to reduce the risk of accelerated atherosclerosis.

Special Populations

• Pediatric:
  • Infants (<6 months): Higher incidence of incomplete KD, making diagnosis challenging. Often present with prolonged fever and extreme irritability, sometimes with only 1-2 classic criteria. Higher risk of developing CAAs and resistance to IVIG therapy. Aggressive diagnostic workup and early echocardiography are crucial.
  • Older Children (>8 years): May present atypically, with more prominent arthralgia/arthritis, sometimes resembling other rheumatologic conditions. Still at risk for CAAs.
• Geriatric: Kawasaki disease is almost exclusively a pediatric disease. It is exceedingly rare in adults. When seen in adults, it is usually a diagnosis of exclusion and may present with systemic vasculitis or fever of unknown origin. Management principles are similar, but diagnostic challenges are greater.
• Pregnancy: Kawasaki disease is not a disease of pregnancy. However, women with a history of KD (especially with residual CAAs) should be managed as high-risk cardiovascular patients during pregnancy. They require close monitoring by a cardiologist and obstetrician due to increased cardiac workload during gestation. Aspirin use during pregnancy, especially in the third trimester, needs careful consideration (low-dose aspirin for antiplatelet effect is generally considered safe, but high-dose is not).
• Comorbidities:
  • Immunodeficiency: Rare, but may affect presentation and response to IVIG.
  • Chronic Inflammatory Conditions: May complicate diagnostic workup and interpretation of inflammatory markers.
  • Viral Infections (e.g., Influenza, Varicella): Children on aspirin therapy for KD have an increased risk of Reye syndrome if they contract influenza or varicella. Annual influenza vaccination is crucial, and varicella vaccination should be up-to-date. If exposed, consider temporarily stopping aspirin and/or using IVIG if high risk for Reye syndrome.

Clinical Pearls

• Diagnostic:
  • Fever is King: Prolonged, unexplained fever (>5 days) that is unresponsive to antibiotics is the most consistent and important diagnostic criterion.
  • "Look for the Limbs and Lips": The extremity changes (red, swollen hands/feet, later desquamation) and oral/lip changes (cracked lips, strawberry tongue) are often very characteristic and helpful.
  • Incomplete KD - High Suspicion: In infants with persistent fever and extreme irritability, or with cardiac findings, even with few classic criteria, think of incomplete KD. Don't wait for all 4 criteria.
  • BCG Site Reaction: In endemic areas, erythema and induration at the BCG vaccination site can be a subtle but highly specific sign.
  • Exclusion is Key: KD is a diagnosis of exclusion. Rule out other infections (e.g., adenovirus, measles, scarlet fever, staphylococcal scalded skin syndrome) and rheumatologic conditions.
• Treatment:
  • Time is Myocardium (and Coronary Artery): Early treatment with IVIG within 7-10 days significantly reduces the risk of CAAs. Every day counts.
  • Aspirin Dosing: Ensure correct high-dose for anti-inflammatory effect during acute fever, followed by low-dose for antiplatelet effect.
  • Refractory Cases: Do not hesitate to re-treat with a second dose of IVIG or consider corticosteroids/infliximab if fever persists beyond 36 hours post-initial IVIG. Early cardiology consultation for refractory cases.
• Pitfalls:
  • Delayed Diagnosis: Missing incomplete KD, especially in infants, leading to higher CAA rates.
  • Stopping Aspirin Too Soon: Discontinuing low-dose aspirin prematurely before appropriate follow-up echocardiograms confirm no CAAs or before platelet counts normalize.
  • Over-reliance on Labs: While labs are supportive, KD is a clinical diagnosis. Normal inflammatory markers in the very early stages or resolution later should not rule out the diagnosis if clinical suspicion is high.
  • Misinterpreting ECG Changes: ECG changes (e.g., T-wave abnormalities, prolonged PR interval) may suggest myocarditis but are non-specific. Echocardiography is key for cardiac assessment.

Recent Updates

• Guidelines: The 2017 American Heart Association (AHA) Scientific Statement for the Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease remains the primary comprehensive guideline, providing updated algorithms for incomplete KD, management of refractory disease, and long-term follow-up.
• Evidence:
  • Biomarkers: Ongoing research into novel biomarkers (e.g., specific RNA signatures, microRNAs) that might aid in earlier diagnosis, predict IVIG resistance, or identify patients at higher risk for CAAs.
  • COVID-19 and MIS-C: The COVID-19 pandemic led to the recognition of Multisystem Inflammatory Syndrome in Children (MIS-C), which shares many clinical features with KD. Research is active in differentiating these two conditions and understanding their pathogenesis, as both can cause coronary artery abnormalities. Treatment strategies often overlap (IVIG, corticosteroids).
  • Refractory KD Therapies: Further evidence accumulating on the efficacy and safety of newer immunomodulators (e.g., infliximab, cyclosporine, tocilizumab) for IVIG-refractory KD.
• Controversies:
  • Optimal initial Aspirin Dose: While 80-100 mg/kg/day was historically used, many centers now use 30-50 mg/kg/day without clear evidence of increased CAA rates, potentially reducing aspirin toxicity.
  • Role of Adjunctive Corticosteroids: While well-established for refractory KD, the routine use of corticosteroids as initial adjunctive therapy to IVIG (e.g., in high-risk patients) remains an area of debate, with some studies showing benefit and others not.
  • Long-term Management of Small CAAs: The optimal frequency of follow-up and the duration of antiplatelet therapy for regressed or very small persistent CAAs are still debated.

Key References

• Guidelines:
  • McCrindle, B. W., et al. (2017). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 135(17), e926-e999. (The primary reference)
  • Japanese Society of Pediatric Cardiology and Cardiac Surgery. (2020). Guidelines for diagnosis and management of Kawasaki disease (revision of the 2014 guidelines). Circulation Journal, 84(11), 1999-2022.
• Studies:
  • Newburger, J. W., et al. (1986). A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine, 315(6), 341-347. (Landmark study establishing IVIG efficacy).
  • Terai, M., & Shiraishi, H. (2000). Efficacy of two-dose intravenous gamma globulin for Kawasaki disease. Journal of Pediatrics, 136(6), 735-738. (Demonstrated benefit of second IVIG dose in refractory cases).
• Reviews:
  • Burns, J. C., & Dufresne, M. (2020). Kawasaki Disease. Nelson Textbook of Pediatrics, 21st ed. Elsevier. (Comprehensive textbook chapter)
  • Eleftheriou, D., et al. (2019). Kawasaki disease. Lancet, 393(10178), 1607-1620. (Excellent review of pathogenesis, diagnosis, and management).